Lovastatin potentiates the antidepressant efficacy of fluoxetine in rats

Pharmacology Biochemistry and Behavior

Volumn 92, Issue 1, 2009, Pages 88-92

  Renshaw, Perry F ^a,d,e   Parsegian, Aram ^a   Yang, C Kevin ^a   Novero, Aileen ^a   Yoon, Sujung J ^b   Lyoo, In Kyoon ^a,c   Cohen, Bruce M ^a   Carlezon Jr , William A ^a  

^a MCLEAN HOSPITAL   (United States)

^b The Catholic University of Korea College of Medicine   (South Korea)

^c Seoul National University Hospital   (South Korea)

^d UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^e VISN 19 MIRECC ^*  (United States)

Author keywords

Cholesterol; Depression; Model; Rat; Serotonin; Statin

Indexed keywords

FLUOXETINE; MEVINOLIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FORCED SWIMMING TEST; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; DIET; DRUG SYNERGISM; FLUOXETINE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOVASTATIN; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; SWIMMING;

RATTUS;

EID: 58749084093     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.10.017     Document Type: Article

References (52)

1. Alexopoulos G.S., Meyers B.S., Young R.C., Campbell S., Silbersweig D., and Charlson M. 'Vascular depression' hypothesis. Arch Gen Psychiatry 54 (1997) 915-922
2. Armitage J. The safety of statins in clinical practice. Lancet 370 (2007) 1781-1790
3. Barradas M.A., Mikhailidis D.P., and Winder A.F. Low serum cholesterol and suicide. Lancet 339 (1992) 1168
4. Borsini F., and Meli A. Is the forced swimming test a suitable model for revealing antidepressant activity?. Psychopharmacology (Berl) 94 (1988) 147-160
5. Brown S.L., Salive M.E., Harris T.B., Simonsick E.M., Guralnik J.M., and Kohout F.J. Low cholesterol concentrations and severe depressive symptoms in elderly people. BMJ 308 (1994) 1328-1332
6. Carlezon W.A., Pliakas A.M., Parow A.M., Detke M.J., Cohen B.M., and Renshaw P.F. Antidepressant-like effects of cytidine in the forced swim test in rats. Biol Psychiatry 51 (2002) 882-889
7. Carlezon Jr. W.A., Mague S.D., Parow A.M., Stoll A.L., Cohen B.M., and Renshaw P.F. Antidepressant-like effects of uridine and omega-3 fatty acids are potentiated by combined treatment in rats. Biol Psychiatry 57 (2005) 343-350
8. Cohen R.A., Zitnay K.M., Haudenschild C.C., and Cunningham L.D. Loss of selective endothelial cell vasoactive functions caused by hypercholesterolemia in pig coronary arteries. Circ Res 63 (1988) 903-910
9. Cucchiara B., and Kasner S.E. Use of statins in CNS disorders. J Neurol Sci 187 (2001) 81-89
10. Delva N.J., Matthews D.R., and Cowen P.J. Brain serotonin (5-HT) neuroendocrine function in patients taking cholesterol-lowering drugs. Biol Psychiatry 39 (1996) 100-106
11. Detke M.J., Rickels M., and Lucki I. Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 121 (1995) 66-72
12. Dietschy J.M., and Turley S.D. Cholesterol metabolism in the brain. Curr Opin Lipidol 12 (2001) 105-112
13. Downs J.R., Oster G., and Santanello N.C. HMG CoA reductase inhibitors and quality of life. JAMA 269 (1993) 3107-3108
14. Engelberg H. Low serum cholesterol and suicide. Lancet 339 (1992) 727-729
15. Farmer J.A., and Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Safety 23 (2000) 197-213
16. Fava M., and Davidson K.G. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19 (1996) 179-200
17. Freedman D.S., Byers T., Barrett D.H., Stroup N.E., Eaker E., and Monroe-Blum H. Plasma lipid levels and psychologic characteristics in men. Am J Epidemiol 141 (1995) 507-517
18. Goldstein J.L., and Brown M.S. Molecular medicine. The cholesterol quartet. Science 292 (2001) 1310-1312
19. Guillot F., Misslin P., and Lemaire M. Comparison of fluvastatin and lovastatin blood-brain barrier transfer using in vitro and in vivo methods. J Cardiovasc Pharmacol 21 (1993) 339-346
20. Hawton K., and Morgan H.G. Suicide prevention by general practitioners. Br J Psychiatry 162 (1993) 422
21. Heron D.S., Shinitzky M., Hershkowitz M., and Samuel D. Lipid fluidity markedly modulates the binding of serotonin to mouse brain membranes. Proc Natl Acad Sci U S A 77 (1980) 7463-7467
22. Iosifescu D.V., Clementi-Craven N., Fraguas R., Papakostas G.I., Petersen T., Alpert J.E., et al. Cardiovascular risk factors may moderate pharmacological treatment effects in major depressive disorder. Psychosom Med 67 (2005) 703-706
23. Jick H., Zornberg G.L., Jick S.S., Seshadri S., and Drachman D.A. Statins and the risk of dementia. Lancet 356 (2000) 1627-1631
24. Kirsch C., Eckert G.P., and Mueller W.E. Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem Pharmacol 65 (2003) 843-856
25. Lamping K.G., Nuno D.W., Chappell D.A., and Faraci F.M. Agonist-specific impairment of coronary vascular function in genetically altered, hyperlipidemic mice. Am J Physiol 276 (1999) R1023-1029
26. Maxfield F.R., and Tabas I. Role of cholesterol and lipid organization in disease. Nature 438 (2005) 612-621
27. Muldoon M.F., Manuck S.B., and Matthews K.A. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. BMJ 301 (1990) 309-314
28. Muller N., and Schwarz M.J. The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 12 (2007) 988-1000
29. Papakostas G.I., Petersen T., Mischoulon D., Hughes M.E., Alpert J.E., Nierenberg A.A., et al. Serum cholesterol and serotonergic function in major depressive disorder. Psychiatry Res 118 (2003) 137-145
30. Papakostas G.I., Petersen T., Sonawalla S.B., Merens W., Iosifescu D.V., Alpert J.E., et al. Serum cholesterol in treatment-resistant depression. Neuropsychobiology 47 (2003) 146-151
31. Papakostas G.I., Iosifescu D.V., Petersen T., Hamill S.K., Alpert J.E., Nierenberg A.A., et al. Serum cholesterol in the continuation phase of pharmacotherapy with fluoxetine in remitted major depressive disorder. J Clin Psychopharmacol 24 (2004) 467-469
32. Papakostas G.I., Ongur D., Iosifescu D.V., Mischoulon D., and Fava M. Cholesterol in mood and anxiety disorders: review of the literature and new hypotheses. Eur Neuropsychopharmacol 14 (2004) 135-142
33. Pardridge W.M., and Mietus L.J. Palmitate and cholesterol transport through the blood-brain barrier. J Neurochem 34 (1980) 463-466
34. Pliakas A.M., Carlson R.R., Neve R.L., Konradi C., Nestler E.J., and Carlezon Jr. W.A. Altered responsiveness to cocaine and increased immobility in the forced swim test associated with elevated cAMP response element-binding protein expression in nucleus accumbens. J Neurosci 21 (2001) 7397-7403
35. Porsolt R.D., Bertin A., and Jalfre M. Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229 (1977) 327-336
36. Porsolt R.D., Le Pichon M., and Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 266 (1977) 730-732
37. Pucadyil T.J., and Chattopadhyay A. Role of cholesterol in the function and organization of G-protein coupled receptors. Prog Lipid Res 45 (2006) 295-333
38. Rajanikant G.K., Zemke D., Kassab M., and Majid A. The therapeutic potential of statins in neurological disorders. Curr Med Chem 14 (2007) 103-112
39. Ringo D.L., Lindley S.E., Faull K.F., and Faustman W.O. Cholesterol and serotonin: seeking a possible link between blood cholesterol and CSF 5-HIAA. Biol Psychiatry 35 (1994) 957-959
40. Shimokawa H., and Vanhoutte P.M. Hypercholesterolemia causes generalized impairment of endothelium-dependent relaxation to aggregating platelets in porcine arteries. J Am Coll Cardiol 13 (1989) 1402-1408
41. Smith G.D. Serum cholesterol concentration and postpartum depression. BMJ 314 (1997) 144
42. Sonawalla S.B., Papakostas G.I., Petersen T.J., Yeung A.S., Smith M.M., Sickinger A.H., et al. Elevated cholesterol levels associated with nonresponse to fluoxetine treatment in major depressive disorder. Psychosomatics 43 (2002) 310-316
43. Stroes E., de Bruin T., de Valk H., Erkelens W., Banga J.D., van Rijn H., et al. NO activity in familial combined hyperlipidemia: potential role of cholesterol remnants. Cardiovasc Res 36 (1997) 445-452
44. Thomas A.J., Kalaria R.N., O, and Brien J.T. Depression and vascular disease: what is the relationship?. J Affect Disord 79 (2004) 81-95
45. Tsuji A., Saheki A., Tamai I., and Terasaki T. Transport mechanism of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors at the blood-brain barrier. J Pharmacol Exp Ther 267 (1993) 1085-1090
46. Vecka M., Tvrzicka E., Stankova B., Novak F., Novakova O., and Zak A. Hypolipidemic drugs can change the composition of rat brain lipids. Tohoku J Exp Med 204 (2004) 299-308
47. Waelsch H., Sperry W.M., and Stoyanoff V.A. The influence of growth and myelination on the deposition and metabolism of lipids in the brain. J Biol Chem 140 (1941) 885-897
48. Wardle J., Armitage J., Collins R., Wallendszus K., Keech A., and Lawson A. Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration. Oxford Cholesterol Study Group. BMJ 313 (1996) 75-78
49. Willner P. The validity of animal models of depression. Psychopharmacology (Berl) 83 (1984) 1-16
50. Yang C.C., Jick S.S., and Jick H. Lipid-lowering drugs and the risk of depression and suicidal behavior. Arch Intern Med 163 (2003) 1926-1932
51. Yehuda S., Rabinovitz S., Carasso R.L., and Mostofsky D.I. The role of polyunsaturated fatty acids in restoring the aging neuronal membrane. Neurobiol Aging 23 (2002) 843-853
52. Young-Xu Y., Chan K.A., Liao J.K., Ravid S., and Blatt C.M. Long-term statin use and psychological well-being. J Am Coll Cardiol 42 (2003) 690-697